These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


480 related items for PubMed ID: 27687621

  • 41. Novel multidrug therapy for children with cyclosporine-resistant or -intolerant nephrotic syndrome.
    Aizawa-Yashiro T, Tsuruga K, Watanabe S, Oki E, Ito E, Tanaka H.
    Pediatr Nephrol; 2011 Aug; 26(8):1255-61. PubMed ID: 21479767
    [Abstract] [Full Text] [Related]

  • 42. Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome.
    Novak I, Frank R, Vento S, Vergara M, Gauthier B, Trachtman H.
    Pediatr Nephrol; 2005 Sep; 20(9):1265-8. PubMed ID: 15942779
    [Abstract] [Full Text] [Related]

  • 43. Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.
    Kamei K, Ishikura K, Sako M, Ito S, Nozu K, Iijima K.
    Pediatr Nephrol; 2020 Jan; 35(1):17-24. PubMed ID: 30564879
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group.
    Lancet; 2014 Oct 04; 384(9950):1273-81. PubMed ID: 24965823
    [Abstract] [Full Text] [Related]

  • 47. A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study.
    Li X, Tian J, Wu J, He Q, Li H, Han F, Li Q, Chen Y, Ni Q, Chen J.
    Clin Ther; 2009 Apr 04; 31(4):741-50. PubMed ID: 19446147
    [Abstract] [Full Text] [Related]

  • 48. Prolonged Impairment of Immunological Memory After Anti-CD20 Treatment in Pediatric Idiopathic Nephrotic Syndrome.
    Colucci M, Carsetti R, Serafinelli J, Rocca S, Massella L, Gargiulo A, Lo Russo A, Capponi C, Cotugno N, Porzio O, Onetti Muda A, Palma P, Emma F, Vivarelli M.
    Front Immunol; 2019 Apr 04; 10():1653. PubMed ID: 31379849
    [Abstract] [Full Text] [Related]

  • 49. Rituximab-induced serum sickness in a 6-year-old boy with steroid-dependent nephrotic syndrome.
    Nakamura M, Kanda S, Yoshioka Y, Takahashi C, Owada K, Kajiho Y, Harita Y, Oka A.
    CEN Case Rep; 2020 May 04; 9(2):173-176. PubMed ID: 31970629
    [Abstract] [Full Text] [Related]

  • 50. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy.
    Yang T, Nast CC, Vo A, Jordan SC.
    Nephrol Dial Transplant; 2008 Jan 04; 23(1):377-80. PubMed ID: 17981884
    [No Abstract] [Full Text] [Related]

  • 51. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
    Ravani P, Bonanni A, Rossi R, Caridi G, Ghiggeri GM.
    Clin J Am Soc Nephrol; 2016 Apr 07; 11(4):710-20. PubMed ID: 26585985
    [Abstract] [Full Text] [Related]

  • 52. Rituximab in treatment of idiopathic glomerulopathy.
    El-Reshaid K, Sallam HT, Hakim AA, Al-Attiyah R.
    Saudi J Kidney Dis Transpl; 2012 Sep 07; 23(5):973-8. PubMed ID: 22982909
    [Abstract] [Full Text] [Related]

  • 53. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome.
    Fujinaga S, Ohtomo Y, Umino D, Takemoto M, Shimizu T, Yamashiro Y, Kaneko K.
    Pediatr Nephrol; 2007 Jan 07; 22(1):71-6. PubMed ID: 17086405
    [Abstract] [Full Text] [Related]

  • 54. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated.
    Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J.
    Nephrol Dial Transplant; 2007 Aug 07; 22(8):2183-93. PubMed ID: 17504846
    [Abstract] [Full Text] [Related]

  • 55. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K, Rituximab for Childhood-Onset Refractory Nephrotic Syndrome (RCRNS) Study Group.
    Pediatr Nephrol; 2017 Nov 07; 32(11):2071-2078. PubMed ID: 28664242
    [Abstract] [Full Text] [Related]

  • 56. Ofatumumab for rituximab-resistant nephrotic syndrome.
    Basu B.
    N Engl J Med; 2014 Mar 27; 370(13):1268-70. PubMed ID: 24670185
    [No Abstract] [Full Text] [Related]

  • 57. Pediatric idiopathic nephrotic syndrome: treatment strategies in steroid dependent and steroid resistant forms.
    Ulinski T, Aoun B.
    Curr Med Chem; 2010 Mar 27; 17(9):847-53. PubMed ID: 20156172
    [Abstract] [Full Text] [Related]

  • 58. Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndrome.
    Dehoux L, Hogan J, Dossier C, Fila M, Niel O, Maisin A, Macher MA, Kwon T, Baudouin V, Deschênes G.
    Pediatr Nephrol; 2016 Nov 27; 31(11):2095-101. PubMed ID: 27263020
    [Abstract] [Full Text] [Related]

  • 59. Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing.
    Wu B, Mao J, Shen H, Fu H, Wang J, Liu A, Gu W, Shu Q, Du L.
    Nephrology (Carlton); 2015 Jan 27; 20(1):18-24. PubMed ID: 25312783
    [Abstract] [Full Text] [Related]

  • 60. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
    Kamei K, Ogura M, Sato M, Sako M, Iijima K, Ito S.
    Pediatr Nephrol; 2016 Jan 27; 31(1):89-95. PubMed ID: 26341251
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 24.